Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Eton Pharmaceuticals (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025.
The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss the results. Investors can participate via phone using the dial-in numbers (800) 715-9871 or (646) 307-1963 with Conference ID 5899895, or through the webcast available on Eton's investor relations website. Management will address both live questions and emailed inquiries sent to investorrelations@etonpharma.com.
Eton Pharmaceuticals (Nasdaq: ETON), un'azienda farmaceutica specializzata in trattamenti per malattie rare, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per giovedì 7 agosto 2025.
L'azienda terrà una conference call e una trasmissione audio in streaming alle 16:30 ET per discutere i risultati. Gli investitori possono partecipare telefonicamente chiamando i numeri (800) 715-9871 o (646) 307-1963 con ID conferenza 5899895, oppure tramite il webcast disponibile sul sito web delle relazioni con gli investitori di Eton. La direzione risponderà sia alle domande in diretta sia a quelle inviate via email all'indirizzo investorrelations@etonpharma.com.
Eton Pharmaceuticals (Nasdaq: ETON), una compañía farmacéutica especializada en tratamientos para enfermedades raras, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el jueves 7 de agosto de 2025.
La empresa realizará una llamada en conferencia y una transmisión de audio en vivo a las 4:30 p.m. ET para discutir los resultados. Los inversores pueden participar por teléfono usando los números (800) 715-9871 o (646) 307-1963 con ID de conferencia 5899895, o a través del webcast disponible en el sitio web de relaciones con inversionistas de Eton. La dirección responderá tanto a preguntas en vivo como a consultas enviadas por correo electrónico a investorrelations@etonpharma.com.
Eton Pharmaceuticals (나스닥: ETON)은 희귀 질환 치료제를 전문으로 하는 제약 회사로, 2025년 2분기 재무 실적 발표를 2025년 8월 7일 목요일에 예정하고 있습니다.
회사는 결과를 논의하기 위해 동부 표준시 오후 4시 30분에 컨퍼런스 콜과 오디오 웹캐스트를 진행할 예정입니다. 투자자들은 전화번호 (800) 715-9871 또는 (646) 307-1963번으로 회의 ID 5899895를 사용해 참여하거나, Eton 투자자 관계 웹사이트에서 제공되는 웹캐스트를 통해 참여할 수 있습니다. 경영진은 실시간 질문과 investorrelations@etonpharma.com으로 보내진 이메일 문의에 모두 답변할 예정입니다.
Eton Pharmaceuticals (Nasdaq : ETON), une société pharmaceutique spécialisée dans les traitements des maladies rares, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le jeudi 7 août 2025.
L'entreprise organisera une conférence téléphonique et une diffusion audio en direct à 16h30 ET pour discuter des résultats. Les investisseurs peuvent participer par téléphone en composant les numéros (800) 715-9871 ou (646) 307-1963 avec l'ID de conférence 5899895, ou via le webcast disponible sur le site des relations investisseurs d'Eton. La direction répondra aux questions en direct ainsi qu'aux demandes envoyées par courriel à investorrelations@etonpharma.com.
Eton Pharmaceuticals (Nasdaq: ETON), ein Pharmaunternehmen, das sich auf die Behandlung seltener Krankheiten spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Donnerstag, den 7. August 2025 geplant.
Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und einen Audio-Webcast abhalten, um die Ergebnisse zu besprechen. Investoren können telefonisch unter den Nummern (800) 715-9871 oder (646) 307-1963 mit der Konferenz-ID 5899895 teilnehmen oder den Webcast auf der Investor-Relations-Website von Eton verfolgen. Das Management wird sowohl Live-Fragen als auch per E-Mail an investorrelations@etonpharma.com gesendete Anfragen beantworten.
- None.
- None.
DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Dial In: (800) 715-9871 or (646) 307-1963; Conference ID: 5899895
Webcast: Click Here
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals, Inc.
FAQ
When will Eton Pharmaceuticals (ETON) report Q2 2025 earnings?
How can investors participate in Eton Pharmaceuticals' Q2 2025 earnings call?
Where can I find the replay of Eton Pharmaceuticals' Q2 2025 earnings webcast?
Can investors submit questions for Eton Pharmaceuticals' Q2 2025 earnings call?
